Medtronic Reports Strong Q3 FY26 Results with 6% Organic Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy MDT?
Source: PRnewswire
- Significant Revenue Growth: Medtronic reported worldwide revenue of $9.017 billion for Q3 FY26, reflecting an 8.7% year-over-year increase, with organic revenue growth of 6%, surpassing market expectations and demonstrating the strength of its product portfolio.
- Strong Cardiac Ablation Solutions: The cardiovascular portfolio grew by 11% year-over-year, with cardiac ablation solutions skyrocketing by 80%, driven by the successful rollout of pulsed field ablation technology, further solidifying Medtronic's leadership in cardiac care.
- Improved Profitability: The company achieved a GAAP operating profit of $1.464 billion with an operating margin of 16.2%, while non-GAAP operating profit reached $2.177 billion with a margin of 24.1%, showcasing success in cost control and efficiency improvements.
- Optimistic Future Outlook: Medtronic reiterated its FY26 organic revenue growth guidance of approximately 5.5% and projected diluted non-GAAP EPS between $5.62 and $5.66, despite facing an estimated $185 million impact from tariffs, reflecting confidence in future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 100.880
Low
102.00
Averages
111.76
High
120.00
Current: 100.880
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medtronic Reports Strong Q3 FY26 Results with 6% Organic Growth
- Significant Revenue Growth: Medtronic reported worldwide revenue of $9.017 billion for Q3 FY26, reflecting an 8.7% year-over-year increase, with organic revenue growth of 6%, surpassing market expectations and demonstrating the strength of its product portfolio.
- Strong Cardiac Ablation Solutions: The cardiovascular portfolio grew by 11% year-over-year, with cardiac ablation solutions skyrocketing by 80%, driven by the successful rollout of pulsed field ablation technology, further solidifying Medtronic's leadership in cardiac care.
- Improved Profitability: The company achieved a GAAP operating profit of $1.464 billion with an operating margin of 16.2%, while non-GAAP operating profit reached $2.177 billion with a margin of 24.1%, showcasing success in cost control and efficiency improvements.
- Optimistic Future Outlook: Medtronic reiterated its FY26 organic revenue growth guidance of approximately 5.5% and projected diluted non-GAAP EPS between $5.62 and $5.66, despite facing an estimated $185 million impact from tariffs, reflecting confidence in future growth prospects.
See More
Medtronic Exceeds Earnings Expectations with Strong Revenue Growth
- Strong Earnings Report: Medtronic reported a non-GAAP EPS of $1.36, beating expectations by $0.02, which underscores the company's robust performance in the medical device sector and reinforces its market leadership.
- Revenue Growth: The company achieved revenues of $9 billion, surpassing the market expectation of $8.99 billion, reflecting sustained demand for its products, particularly in the cardiovascular and neuromodulation segments.
- Healthcare Sector Strength: The overall healthcare sector shows strong revenue growth momentum, which may provide a favorable backdrop for Medtronic's future market expansion efforts.
- Dividend Appeal: Medtronic is recognized as a dividend aristocrat, attracting investor interest, and its stable dividend policy could enhance investor confidence and drive stock price appreciation.
See More
Medtronic Reports Q3 FY2026 Results Amid Tariff Challenges
- Financial Performance: Medtronic reported a non-GAAP EPS of $1.36 for Q3 FY2026, beating consensus by $0.02, with revenue of $9 billion reflecting approximately 9% YoY growth, showcasing the company's resilience amid challenges.
- Revenue Outlook: The company reaffirmed its FY2026 outlook, projecting about 5.5% organic revenue growth despite facing a $185 million headwind from tariffs, and estimates a 4.5% growth in diluted non-GAAP EPS excluding tariff impacts, outperforming analysts' 2.9% expectations.
- Business Drivers: The cardiovascular segment drove significant growth, contributing $3.5 billion in revenue with a 14% YoY increase, while the diabetes unit also supported growth with $796 million in revenue, benefiting from double-digit growth in international markets.
- Profit Pressure: Despite revenue growth, Medtronic's adjusted net income fell approximately 2% YoY to $1.8 billion, with non-GAAP operating margin decreasing from 26.2% to 24.1%, indicating cost pressures and market challenges.
See More
Medtronic Exceeds Earnings Expectations with Strong Revenue Growth
- Strong Earnings Report: Medtronic reported a non-GAAP EPS of $1.36, beating expectations by $0.02, which reflects the company's ongoing improvement in profitability and boosts investor confidence.
- Revenue Growth: The company achieved revenues of $9 billion, surpassing market expectations of $8.99 billion, indicating robust performance in the medical device market and likely driving future investments and expansions.
- Industry Performance: The healthcare sector shows a strong revenue growth trend, reflecting sustained demand for medical devices, which provides a favorable external environment for Medtronic's business development.
- Dividend Appeal: Medtronic is recognized as a dividend aristocrat, attracting investors seeking stable income, and the company's financial performance and dividend policy are expected to enhance its market appeal.
See More
Medtronic Q3 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Medtronic reported a Q3 non-GAAP EPS of $1.36, beating expectations by $0.02, which reflects the company's robust profitability and enhances market confidence in its future performance.
- Revenue Growth: The company achieved worldwide revenue of $9.017 billion, an 8.7% year-over-year increase that exceeded expectations by $110 million, indicating strong performance across multiple business segments, particularly in cardiovascular and diabetes.
- Segment Performance: The cardiovascular portfolio generated $3.457 billion in revenue, a 13.8% increase, with high-single-digit growth in cardiac rhythm and heart failure products, showcasing a strong recovery in market demand.
- Future Outlook: Medtronic reiterated its FY26 organic revenue growth guidance of approximately 5.5%, despite a potential $185 million impact from tariffs, while still projecting a 4.5% growth in EPS, demonstrating management's confidence in future prospects.
See More
Medtronic Reports Stronger-Than-Projected Earnings, Yet Stock Declines. Here's the Reason.
- Earnings Performance: Medtronic reported earnings and net sales that exceeded consensus expectations.
- Stock Reaction: Despite the positive earnings report, the stock experienced a decline in premarket trading on Tuesday.
See More
Medtronic Reports Strong Q3 FY26 Results with 6% Organic Growth
- Significant Revenue Growth: Medtronic reported worldwide revenue of $9.017 billion for Q3 FY26, reflecting an 8.7% year-over-year increase, with organic revenue growth of 6%, surpassing market expectations and demonstrating the strength of its product portfolio.
- Strong Cardiac Ablation Solutions: The cardiovascular portfolio grew by 11% year-over-year, with cardiac ablation solutions skyrocketing by 80%, driven by the successful rollout of pulsed field ablation technology, further solidifying Medtronic's leadership in cardiac care.
- Improved Profitability: The company achieved a GAAP operating profit of $1.464 billion with an operating margin of 16.2%, while non-GAAP operating profit reached $2.177 billion with a margin of 24.1%, showcasing success in cost control and efficiency improvements.
- Optimistic Future Outlook: Medtronic reiterated its FY26 organic revenue growth guidance of approximately 5.5% and projected diluted non-GAAP EPS between $5.62 and $5.66, despite facing an estimated $185 million impact from tariffs, reflecting confidence in future growth prospects.
See More
Medtronic Exceeds Earnings Expectations with Strong Revenue Growth
- Strong Earnings Report: Medtronic reported a non-GAAP EPS of $1.36, beating expectations by $0.02, which underscores the company's robust performance in the medical device sector and reinforces its market leadership.
- Revenue Growth: The company achieved revenues of $9 billion, surpassing the market expectation of $8.99 billion, reflecting sustained demand for its products, particularly in the cardiovascular and neuromodulation segments.
- Healthcare Sector Strength: The overall healthcare sector shows strong revenue growth momentum, which may provide a favorable backdrop for Medtronic's future market expansion efforts.
- Dividend Appeal: Medtronic is recognized as a dividend aristocrat, attracting investor interest, and its stable dividend policy could enhance investor confidence and drive stock price appreciation.
See More
Medtronic Reports Q3 FY2026 Results Amid Tariff Challenges
- Financial Performance: Medtronic reported a non-GAAP EPS of $1.36 for Q3 FY2026, beating consensus by $0.02, with revenue of $9 billion reflecting approximately 9% YoY growth, showcasing the company's resilience amid challenges.
- Revenue Outlook: The company reaffirmed its FY2026 outlook, projecting about 5.5% organic revenue growth despite facing a $185 million headwind from tariffs, and estimates a 4.5% growth in diluted non-GAAP EPS excluding tariff impacts, outperforming analysts' 2.9% expectations.
- Business Drivers: The cardiovascular segment drove significant growth, contributing $3.5 billion in revenue with a 14% YoY increase, while the diabetes unit also supported growth with $796 million in revenue, benefiting from double-digit growth in international markets.
- Profit Pressure: Despite revenue growth, Medtronic's adjusted net income fell approximately 2% YoY to $1.8 billion, with non-GAAP operating margin decreasing from 26.2% to 24.1%, indicating cost pressures and market challenges.
See More
Medtronic Exceeds Earnings Expectations with Strong Revenue Growth
- Strong Earnings Report: Medtronic reported a non-GAAP EPS of $1.36, beating expectations by $0.02, which reflects the company's ongoing improvement in profitability and boosts investor confidence.
- Revenue Growth: The company achieved revenues of $9 billion, surpassing market expectations of $8.99 billion, indicating robust performance in the medical device market and likely driving future investments and expansions.
- Industry Performance: The healthcare sector shows a strong revenue growth trend, reflecting sustained demand for medical devices, which provides a favorable external environment for Medtronic's business development.
- Dividend Appeal: Medtronic is recognized as a dividend aristocrat, attracting investors seeking stable income, and the company's financial performance and dividend policy are expected to enhance its market appeal.
See More
Medtronic Q3 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Medtronic reported a Q3 non-GAAP EPS of $1.36, beating expectations by $0.02, which reflects the company's robust profitability and enhances market confidence in its future performance.
- Revenue Growth: The company achieved worldwide revenue of $9.017 billion, an 8.7% year-over-year increase that exceeded expectations by $110 million, indicating strong performance across multiple business segments, particularly in cardiovascular and diabetes.
- Segment Performance: The cardiovascular portfolio generated $3.457 billion in revenue, a 13.8% increase, with high-single-digit growth in cardiac rhythm and heart failure products, showcasing a strong recovery in market demand.
- Future Outlook: Medtronic reiterated its FY26 organic revenue growth guidance of approximately 5.5%, despite a potential $185 million impact from tariffs, while still projecting a 4.5% growth in EPS, demonstrating management's confidence in future prospects.
See More
Medtronic Reports Stronger-Than-Projected Earnings, Yet Stock Declines. Here's the Reason.
- Earnings Performance: Medtronic reported earnings and net sales that exceeded consensus expectations.
- Stock Reaction: Despite the positive earnings report, the stock experienced a decline in premarket trading on Tuesday.
See More
